New "morning-after" pill safe, effective: FDA staff
Key points
- A new, longer-lasting "morning-after" pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.
- Data shows the one-pill treatment, called "ella" and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.
- At the meeting, FDA's panel of outside experts will decide whether to recommend the agency approve the drug for the U.S. market.
- The HRA Pharma drug, already approved for use in Europe under the name ellaOne, has re-ignited debate over "morning-after" pills in the United States, where reproductive issues are a constant political issue.
A new, longer-lasting "morning-after" pill to prevent unwanted pregnancy appears to work with no unexpected side effects, U.S. health regulatory staff said in documents released on Tuesday.
Data shows the one-pill treatment, called "ella" and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.
At the meeting, FDA's panel of outside experts will decide whether to recommend the agency approve the drug for the U.S. market. If approved, Watson Pharmaceutical would sell the drug in the United States.
The HRA Pharma drug, already approved for use in Europe under the name ellaOne, has re-ignited debate over "morning-after" pills in the United States, where reproductive issues are a constant political issue.
Women's health advocates have welcomed the potential for another emergency contraceptive option, but some critics contend the drug is more akin to the abortion pill, sold by Danco Laboratories as Mifeprex and also known as RU-486 or mifepristone.
HRA Pharma has said its drug, whose scientific name is ulipristal, works by preventing ovulation of a woman's egg.
In their review, FDA staff scientists said the company's studies showed no unexpected side effects in women, although reports of nausea, headache and abdominal pain were common. It was not clear what effect the drug had, if any, when a woman still became pregnant despite taking it, they added.
"Data on pregnancy outcomes after EC (emergency contraceptive) failure with ulipristal were too limited to draw any definitive conclusions regarding the effect of ulipristal on an established pregnancy or fetal development," they wrote.
--
WASHINGTON (Reuters)
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Pregnancy & Fertility →
NewsUGA study finds weight training safe for pregnant women
Despite decades of doctors’ reluctance to recommend weight training to pregnant women, a new University of Georgia study has found that a supervised, low-to-moderate intensity program is safe and beneficial. The…
26 March 2011
NewsCO woman waits to see if pill mix up harmed embryo
Doctors say the early stages of pregnancy are an especially bad time for a pharmacological mix-up where a woman prescribed antibiotics instead is given a powerful drug used in chemotherapy. Yet a pharmacist at a…
11 February 2011
NewsOvercoming real-life on "the Pill"
Oral contraceptives boast annual unintended pregnancy rates well below 1 percent - if used correctly and consistently, that is. But in the not-so-perfect real world, longer lasting ingredients and shorter monthly breaks…
